Home / Peptides / MOTS-c

MOTS-c Dosage: What the Evidence Says (2026)

Not FDA-approved

16-amino-acid mitochondrial peptide studied in animals. Not approved; no human data for MOTS-c itself.

Also called: mitochondrial ORF of the 12S rRNA-c

Regulatory status (US)

Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names injection under the skin or into muscle.

What it is

A 16-amino-acid peptide encoded in mitochondrial DNA, studied in animals for effects on metabolism.

Dosage

No established human dose. No FDA label or published dose-finding trial gives a dose for MOTS-c. Numbers you see on seller sites or forums are not based on reviewed human studies, so we do not list them.

MOTS-c reconstitution calculator

Enter your vial and your prescribed dose to see the units on a U-100 syringe.

–
Concentration–
Per 1 unit (0.01 mL)–
Volume per dose–
Doses per vial–

What human studies show

Safety

Questions

Is MOTS-c FDA-approved?
Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names injection under the skin or into muscle.
What dose of MOTS-c has been studied?
There is no established human dose. Native MOTS-c: no human exposure data (FDA). A modified analogue, CB4211, was tested at 25 mg daily for 4 weeks in 20 people with obesity and fatty liver. That is a different molecule.
How many units is my MOTS-c dose?
Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.

Related

Sermorelin

The first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.

BPC-157

15-amino-acid peptide studied mostly in animals. Not approved; no established human dose.

TB-500 (thymosin beta-4)

Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.

GHK-Cu (copper peptide)

Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.

Sources

  1. FDA: Certain bulk drug substances for compounding that may present significant safety risks
  2. Federal Register (public inspection) 2026-07361: peptide category changes
  3. PharmExec: FDA advisory committee votes to loosen restrictions on peptides (Jul 2026)
  4. Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
  5. CohBar: phase 1a/1b topline results for CB4211 (MOTS-c analogue)
  6. FDA 510(k) K212499: BD insulin syringes for U-100 insulin

Last checked 2026-11-16. How we pick and check sources: methodology.